Alx Oncology Holdings Inc (ALXO)
$6.05
Performance
- $5.99$6.38$6.05
0.99%
Downside
Day's Volatility :6.09%
Upside
5.15%
- $3.94$17.83$6.05
34.88%
Downside
52 Weeks Volatility :77.9%
Upside
66.07%
Returns
| Period | Alx Oncology Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -63.82% | 6.5% | 0.0% |
6 Months | -58.62% | 7.1% | 0.0% |
1 Year | 4.1% | 9.8% | 0.0% |
3 Years | -89.42% | 14.2% | -20.2% |
Highlights
Market Capitalization | 323.5M |
Book Value | $3.27 |
Earnings Per Share (EPS) | -3.71 |
Wall Street Target Price | 21.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -44.78% |
Return On Equity TTM | -82.16% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 107.0K |
EBITDA | -175.0M |
Diluted Eps TTM | -3.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.89 |
EPS Estimate Next Year | -2.84 |
EPS Estimate Current Quarter | -0.84 |
EPS Estimate Next Quarter | -0.84 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 247.11%
Technicals Summary
Sell
Neutral
Buy
Alx Oncology Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Alx Oncology Holdings Inc | 3.74% | -58.62% | 4.1% | -89.42% | -79.67% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Alx Oncology Holdings Inc | NA | NA | NA | -2.89 | -0.82 | -0.45 | NA | 3.27 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Alx Oncology Holdings Inc | Buy | $323.5M | -79.67% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Alx Oncology Holdings Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 57.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 275.9%
Institutional Holdings
venBio Partners LLC
18.62%FMR Inc
14.44%Redmile Group, LLC
8.30%Vivo Capital, LLC
8.10%Cormorant Asset Management, LLC
6.03%Orbimed Advisors, LLC
5.22%
Company Information
alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com
Organization | Alx Oncology Holdings Inc |
Employees | 74 |
CEO | Dr. Corey S. Goodman Ph.D. |
Industry | Commercial Services |
Discover More
A Spac I Acquisition Corp
$6.05
-0.82%
Keyarch Acquisition Corp
$6.05
-0.82%
Connexa Sports Technologies Inc
$6.05
-0.82%
Us Value Etf
$6.05
-0.82%
First Wave Biopharma Inc
$6.05
-0.82%
Global X Msci Next Emerging
$6.05
-0.82%
Fat Projects Acquisition Corp
$6.05
-0.82%
Capital Link Global Fintech
$6.05
-0.82%
Applied Uv Inc
$6.05
-0.82%